Clinical trials: Alzheimer Dementia
Dementia, Alzheimer Disease
A Multidomain Intervention Program for Older People With Dementia
This is a pilot study to assess the feasibility of a multidomain intervention for older people with dementia in nursing homes. Participants will be randomized into two equal groups, to receive either an intensive multidomain…
- Conditions
- Dementia, Alzheimer Disease, Dementia, Mixed
- Trial name
- NCT04948450
- Testing
- Physical activity intervention, Cognitive stimulation intervention, Social intervention
- Where
- 4 sites in Vietnam
- Volunteers
- 60 people
- Sponsor
- National Geriatric Hospital
Alzheimer's Disease, Apathy
Methylphenidate for Apathy in Alzheimer's Dementia: A Controlled Study
The purpose of the study is to determine the efficacy of methylphenidate over placebo in treating apathy in patients with Alzheimer's dementia.
- Conditions
- Alzheimer's Disease, Apathy, Dementia
- Trial name
- NCT00495820
- Testing
- Methylphenidate
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- VA Office of Research and Development
Alzheimer Disease, Mild Cognitive Impairment
Evaluation of a Computerized Complex Instrumental Activities of Daily Living Marker (NMI)
The proposed study is designed to evaluate the performance of the ALTOIDA™ System as a tool to assist physicians in diagnosing Alzheimer's Disease (AD) in real-world clinical settings.
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment, Memory Disorders, Cognitive Impairment
- Trial name
- AltoidaML (NCT02843529)
- Testing
- Altoida: neuropsychological, MRI, EEG and CSF biomarkers
- Volunteers
- 548 people, healthy volunteers welcome
- Sponsor
- Altoida
Caregivers, Decision Making
"Safety in Dementia": An Online Caregiver Intervention
In an online randomized trial of Safety in Dementia with national recruitment and longitudinal follow-up, we will recruit informal caregivers of community-dwelling adults with dementia who have firearm access.
- Conditions
- Caregivers, Decision Making, Alzheimer Disease, Social Media
- Trial name
- NCT05173922
- Testing
- Safety in Dementia
- Where
- United States
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Irregular Sleep-Wake Rhythm Disorder
Study of Lemborexant for Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia
This study will be conducted to determine the dose response of lemborexant (LEM) on the change from baseline in actigraphy-derived sleep-related parameters, wake-related parameters, and circadian-rhythm related parameters.
- Trial name
- NCT03001557
- Testing
- Lemborexant 2.5 mg, Lemborexant 5 mg, Lemborexant 10 mg
- Where
- 48 sites in United States, Japan and 1 more
- Volunteers
- 63 people
- Sponsor
- Eisai Inc.
Mild Cognitive Impairment, Alzheimer Disease
Study of the Efficacy and Safety of Various Anti-inflammatory Agents in Participants With Mild Cognitive Impairment or Mild Alzheimer's Disease
The purpose of this platform study was to evaluate the effect of anti-inflammatory agents on cognition in early Alzheimer's disease.
- Trial name
- NCT04795466
- Testing
- Canakinumab
- Where
- 10 sites in United States, Finland and 2 more
- Volunteers
- 34 people
- Sponsor
- Novartis Pharmaceuticals
Alzheimer's Disease
A Study of Lanabecestat (LY3314814) in Participants With Mild Alzheimer's Disease Dementia
The main purpose of this study is to evaluate the efficacy of the study drug known as lanabecestat in participants with mild Alzheimer's disease (AD) dementia.
- Trial name
- DAYBREAK-ALZ (NCT02783573)
- Testing
- Lanabecestat
- Where
- 262 sites in United States, Canada and 16 more
- Volunteers
- 1,722 people
- Sponsor
- AstraZeneca
Alzheimer Disease, Early Onset
Pilot Study to Investigate the Safety and Feasibility of AntiRetroviral Therapy for Alzheimer's Disease
The objective of the study is to evaluate the ability of (-)-L-2',3'-dideoxy-3'-thiacytidine (3TC) to engage its intended target, penetrate the central nervous system (CNS), suppress neurodegeneration, and assess safety and…
- Trial name
- ART-AD (NCT04552795)
- Testing
- 3TC
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Alzheimer Disease, Dementia
A Follow-On Study of Donanemab (LY3002813) With Video Assessments in Participants With Alzheimer's Disease (TRAILBLAZER-EXT)
The main goals of this study are to further determine whether the study drug donanemab is safe and effective in participants with Alzheimer's disease and to validate neuropsychological assessments administered over…
- Conditions
- Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases
- Trial name
- NCT04640077
- Testing
- No Intervention, donanemab
- Where
- 27 sites in United States, Canada
- Volunteers
- 95 people
- Sponsor
- Eli Lilly and Company
Alzheimer's Disease
A Study Of PF-04447943 Compared To Placebo In Subjects With Mild To Moderate Alzheimer's Disease
The purpose of this study is to evaluate the effects of PF-04447943 compared to placebo on cognitive, behavioral and overall symptoms of Alzheimer's disease; evaluate the safety and tolerability of PF-0444793 compared to placebo…
- Trial name
- NCT00930059
- Testing
- PF-04447943
- Where
- 44 sites in United States, Canada and 2 more
- Volunteers
- 191 people
- Sponsor
- Pfizer
Alzheimer's Disease
Safety and Efficacy of Donepezil in Mild to Moderate Alzheimer's Disease
This study will evaluate the safety and Efficacy of donepezil in treatment of AD patients in China.
- Trial name
- STDMMAD (NCT02787746)
- Testing
- Donepezil
- Where
- China
- Volunteers
- 241 people
- Sponsor
- Beijing Friendship Hospital
Alzheimer Disease
Bryostatin Treatment of Moderately Severe Alzheimer's Disease
To evaluate the safety, tolerability, and long-term efficacy of bryostatin 1 (hereafter referred to as bryostatin) for the treatment of moderately severe Alzheimer's disease (AD).
- Trial name
- NCT04538066
- Testing
- Bryostatin 1
- Where
- 19 sites in United States
- Volunteers
- 122 people
- Sponsor
- Neurotrope Bioscience, Inc.
Dementia, Alzheimer's Disease
In-Home Technology for Dementia Caregivers
This study aims to develop and evaluate in-home assistive technology that is designed to alleviate anxiety, burden, and loneliness in spousal and familial caregivers of individuals with Alzheimer's disease and frontotemporal…
- Conditions
- Dementia, Alzheimer's Disease, Frontotemporal Dementia
- Trial name
- NCT03828383
- Testing
- In-home technology, Limited in-home technology
- Where
- 5 sites in United States
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- University of California, Berkeley
Alzheimer's Disease
Study of Octagam (Intravenous Immunoglobulin [IVIG]) 10% on the Treatment of Mild to Moderate Alzheimer's Disease
This study evaluated the effect of 6 or 12 infusions of different doses of octagam (intravenous immunoglobulin [IVIG]) 10% on the reduction of amyloid beta peptide (Aβ) in cerebral spinal fluid (CSF) and on the increase of Aβ in…
- Trial name
- NCT00812565
- Testing
- octagam 10%
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- Octapharma
Alzheimer's Disease
Brain Amyloid and Vascular Effects of Eicosapentaenoic Acid
The number of Americans diagnosed with Alzheimer's disease (AD) is expected to triple by 2050. Compared to the general population, Veterans have a greater risk of AD, likely in part due to their increased incidence of traumatic…
- Trial name
- BRAVE-EPA (NCT02719327)
- Testing
- icosapent ethyl (IPE)
- Where
- United States
- Volunteers
- 131 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Alzheimer's Disease
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
The main purpose of this study is to investigate the safety and efficacy of the study drug solanezumab in participants with prodromal Alzheimer's disease (AD).
- Trial name
- ExpeditionPRO (NCT02760602)
- Testing
- Solanezumab
- Where
- 193 sites in United States, Canada and 11 more
- Volunteers
- 26 people
- Sponsor
- Eli Lilly and Company
Depression, Anxiety
IntelliCare Study: Artificial Intelligence in a Mobile (AIM) Intervention for Depression
This study will evaluate and compare a smartphone intervention for depression and anxiety that uses machine learning to tailor treatment for participants with the same intervention without the machine learning component.
- Trial name
- AIM (NCT02801877)
- Testing
- IntelliCare, Hub App with the Recommender System, Coaching
- Where
- United States
- Volunteers
- 301 people
- Sponsor
- Northwestern University
Alzheimer Disease
Transmagnetic Stimulation Pilot in Early Stage Alzheimer's Disease
Alzheimer's disease (AD) is a progressive neurodegenerative condition affecting 6.2 million individuals in the United States, resulting in an annual cost of care of $305 billion.
- Trial name
- NCT05292222
- Testing
- Intermittent theta burst stimulation
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- HealthPartners Institute
Substance Use Disorder (SUD)
A Study of a Mobile Phone Application Measuring the Eyes Before and After Medication
This is a post-market clinical follow-up study on an approved CE-marked eHealth system where a mobile phone application is used to measure the pupils and eye measurements to monitor the use of different drug substances.
- Trial name
- NCT06629740
- Testing
- Measurements with a eHealth system
- Where
- Netherlands
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Kontigo Care AB
Alzheimer Disease
Study Comparing 3 Dosage Levels Of SAM-531 In Outpatients With Mild To Moderate Alzheimer Disease
The study will evaluate the efficacy and safety of an investigational drug called SAM-531 at three dosage levels. Subjects will receive either one of the 3 dosage levels of SAM-531, donepezil or placebo for the first 24 weeks of…
- Trial name
- NCT00895895
- Testing
- SAM-531 1.5 mg, SAM-531 3.0 mg, SAM-531 5.0 mg
- Where
- 96 sites in United States, Argentina and 11 more
- Volunteers
- 526 people
- Sponsor
- Pfizer